Abstracts tagged "Adolescence and Transition"

Abstract Number: 127 • 2017 Pediatric Rheumatology Symposium
Description of first 40 patients from a Rheumatologic Transition Clinic in Chile
Macarena Armstrong¹, Eduardo Talesnik², Paulina Andrea Diaz¹, Arturo Borzutzky² and Pamela Morales², ¹Department of Immunology and Rheumatology, Internal Medicine Division, Pontificia Universidad Católica de Chile, Santiago, Chile, ²Department of Pediatric Infectious Diseases and Immunology, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Transition is the planned, coordinated and continuous process in which an adolescent with chronic rheumatic disease is transferred from the pediatric service to an…
Abstract Number: 1402 • 2016 ACR/ARHP Annual Meeting
Meeting the Needs of Adolescents with Autoimmune Diseases, the Development of a Clinical Transition Pathway
Margot Walter¹, Johanna M.W. Hazes², Radboud JEM Dolhain³, Philomine A. van Pelt⁴, A. Dijk van⁵ and Sylvia S.M. Kamphuis⁶, ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ³Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Sophia Children's Hospital, Erasmusmc, Rotterdam, Netherlands, ⁶Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Centre, Rotterdam, Netherlands
Background/Purpose: Evidence based recommendations for transitional programs are available. Despite this, half of Young People (YP) do not make a successful transfer and implementation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].